​

Sagimet Biosciences (SGMT) Stock Forecast, Price Target & Predictions

OverviewOwnershipFinancialsChart

SGMT Stock Forecast

Sagimet Biosciences (SGMT) stock forecast, based on 4 Wall Street analysts, predicts a 12-month average price target of $6.00, with a high of $6.00 and a low of $6.00. This represents a -37.43% decline from the last price of $9.59.

$2 $3 $4 $5 $6 $7 $8 $9 $10 High: $6 Avg: $6 Low: $6 Last Closed Price: $9.59

SGMT Stock Rating

Sagimet Biosciences stock's rating consensus is Buy, based on 4 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 3 Buy (75.00%), 1 Hold (25.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 4 0 1 3 Strong Sell Sell Hold Buy Strong Buy

SGMT Price Target Upside V Benchmarks

TypeNameUpside
StockSagimet Biosciences-37.43%
SectorHealthcare Stocks 25.53%
IndustryBiotech Stocks 53.82%

Price Target Trends

1M3M12M
# Anlaysts---
Avg Price Target---
Last Closing Price$9.59$9.59$9.59
Upside/Downside---
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Jul, 2525---7
Jun, 2525---7
May, 25351--9
Apr, 25351--9
Mar, 25351--9
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Jun 28, 2024Andrea TanGoldman Sachs$6.00$4.1145.99%-37.43%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Dec 05, 2024OppenheimerOutperforminitialise
Nov 18, 2024H.C. WainwrightBuyBuyhold
Oct 01, 2024Leerink PartnersOutperformOutperformhold
Aug 15, 2024JMP SecuritiesOutperformOutperformhold
Jun 28, 2024Goldman SachsBuyNeutraldowngrade
May 24, 2024Cowen & Co.BuyBuyhold
May 02, 2024H.C. WainwrightBuyinitialise
Aug 08, 2023Piper SandlerOverweightinitialise

Financial Forecast

EPS Forecast

$-40 $-32 $-24 $-16 $-8 $0 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-2.66$-1.45----
Avg Forecast$-37.28$-1.49$-3.34$-4.34$-5.83$-3.58
High Forecast$-37.28$-1.42$-2.83$-0.95$-4.37$-3.58
Low Forecast$-37.28$-1.65$-4.10$-6.80$-7.68$-3.58
Surprise %-92.86%-2.68%----

Revenue Forecast

$0 $30M $60M $90M $120M $150M Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$2.00M-----
Avg Forecast$2.00M$2.00M$1.25M$21.00K$29.40M$100.68M
High Forecast$2.00M$2.00M$1.25M$21.00K$29.40M$100.68M
Low Forecast$2.00M$2.00M$1.25M$21.00K$29.40M$100.68M
Surprise %------

Net Income Forecast

$-400M $-320M $-240M $-160M $-80M $0 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-27.88M$-45.57M----
Avg Forecast$-389.91M$-16.05M$-36.21M$-40.53M$-63.03M$-37.41M
High Forecast$-389.91M$-14.89M$-29.55M$-9.97M$-45.69M$-37.41M
Low Forecast$-389.91M$-17.21M$-42.87M$-71.09M$-80.36M$-37.41M
Surprise %-92.85%183.86%----

SGMT Forecast FAQ

Is Sagimet Biosciences stock a buy?

Sagimet Biosciences stock has a consensus rating of Buy, based on 4 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 3 Buy, 1 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Sagimet Biosciences is a favorable investment for most analysts.

What is Sagimet Biosciences's price target?

Sagimet Biosciences's price target, set by 4 Wall Street analysts, averages $6 over the next 12 months. The price target range spans from $6 at the low end to $6 at the high end, suggesting a potential -37.43% change from the previous closing price of $9.59.

How does Sagimet Biosciences stock forecast compare to its benchmarks?

Sagimet Biosciences's stock forecast shows a -37.43% downside, underperforming the average forecast for the healthcare stocks sector (25.53%) and underperforming the biotech stocks industry (53.82%).

What is the breakdown of analyst ratings for Sagimet Biosciences over the past three months?

  • July 2025: 28.57% Strong Buy, 71.43% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • June 2025: 28.57% Strong Buy, 71.43% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • May 2025: 33.33% Strong Buy, 55.56% Buy, 11.11% Hold, 0% Sell, 0% Strong Sell.

What is Sagimet Biosciences’s EPS forecast?

Sagimet Biosciences's average annual EPS forecast for its fiscal year ending in December 2025 is $-3.34, marking a 130.34% increase from the reported $-1.45 in 2024. Estimates for the following years are $-4.34 in 2026, $-5.83 in 2027, and $-3.58 in 2028.

What is Sagimet Biosciences’s revenue forecast?

Sagimet Biosciences's average annual revenue forecast for its fiscal year ending in December 2025 is $1.25M, reflecting a 0% decrease from the reported $0 in 2024. The forecast for 2026 is $21K, followed by $29.4M for 2027, and $100.68M for 2028.

What is Sagimet Biosciences’s net income forecast?

Sagimet Biosciences's net income forecast for the fiscal year ending in December 2025 stands at $-36.211M, representing a -20.53% decrease from the reported $-45.567M in 2024. Projections indicate $-40.53M in 2026, $-63.025M in 2027, and $-37.413M in 2028.